Semax — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Semax

Also known as: ACTH(4-10) analogue, ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, Semax peptide, ACTH4-7-Pro-Gly-Pro

Synthetic nootropic/neuroprotective heptapeptide; melanocortin-related peptide; ACTH analogue

Research chemicalLast updated: October 31, 2026Based on 42 peer-reviewed studies

What it is

Semax is a neuroprotective peptide approved in Russia for stroke treatment and cognitive decline, widely used in the nootropics community for focus, memory, and mood. It supports the production of nerve growth factors and protects brain cells from damage. Approved in Russia; not FDA-approved; evidence includes Russian clinical trials and animal studies.

The scientific side

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the N-terminal ACTH(4-10) fragment that is devoid of hormonal activity. Its documented or proposed mechanisms include: (1) upregulation of NGF and BDNF gene expression in the hippocampus, frontal cortex, and retina; (2) modulation of GABA-activated ionic currents (potentiation in cerebellar Purkinje cells) and inhibition of glycine-activated chloride currents in hippocampal pyramidal neurons; (3) modulation of intracellular calcium dynamics in hippocampal pyramidal neurons; (4) suppression of proinflammatory gene expression (Il1a, Il1b, Il6, Ccl3, Cxcl2) and activation of neurotransmission-related genes under ischemic conditions (PMID 34097675; PMID 32580520); (5) high-affinity chelation of Cu(II) ions, enabling extraction of copper from Cu-Aβ complexes and reduction of associated ROS production (PMID 40496623; PMID 35080861); (6) inhibition of enkephalin-degrading enzymes in human serum (IC50 10 µM); (7) modulation of brain functional connectivity, particularly affecting the default mode network and amygdala–temporal cortex connectivity (PMID 30225715; PMID 32342318); (8) targeting the µ-opioid receptor (Oprm1), regulating USP18 and deubiquitination of FTO to promote lysosomal membrane stability after spinal cord injury; (9) regulation of VEGF family gene expression in ischemic brain tissue (PMID 22772900; PMID 23888777); (10) immunomodulatory effects via immune response gene expression changes (PMID 24661604; PMID 42021992); (11) antioxidant properties demonstrated by counteracting heavy metal-induced learning inhibition. Metabolically, Semax is cleaved into functional fragments (HFPGP, PGP) that form a "synacton" with distinct receptor binding characteristics.

Class: Synthetic nootropic/neuroprotective heptapeptide; melanocortin-related peptide; ACTH analogue

Modified Forms

The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.

N-Acetyl Semax Amidate

N-Acetyl Semax Amidate adds an N-acetyl group at the N-terminus and an amide group at the C-terminus of the Semax sequence. Both modifications inhibit enzymatic degradation, extending the peptide's biological half-life compared to standard Semax. No peer-reviewed pharmacological or clinical studies specific to this modified form were found in literature searches — all mechanism and efficacy claims are extrapolated from Semax research. Community users often report using it at lower doses than standard Semax under the assumption of greater potency from increased stability, though this assumption lacks published experimental support. Regulatory status is identical to Semax: not approved in any reviewed jurisdiction.

How dosing differs: Community protocols report 100–300 mcg intranasal, often lower than standard Semax (500–600 mcg) due to assumed potency difference from increased enzymatic stability. No published dose-finding data exists for this modified form.

Key differences from parent: N-terminal acetylation + C-terminal amidation increase resistance to peptidase cleavage. Half-life is assumed longer than standard Semax but has not been measured in published studies. No independent mechanism or efficacy studies exist.

Administration & storage

Administration
Intranasal administration (nasal drops) — human and animal studies (PMID: 12459874302257152280313222708068)Endonasal electrophoresis — human optic nerve disease study (PMID: 10741256)Intraperitoneal injection — animal studies (PMID: 3944274633459919327377232857709725464761)Neonatal injection (route not further specified) — neonatal mouse study (PMID: 19145359)
Storage
No storage conditions for Semax are described in the reviewed abstracts.
Cautions
Clinical use has been primarily documented in Russian literature; long-term safety data and large-scale randomized controlled trials are lacking for most indications.,One study in 187 cerebrovascular insufficiency patients reported minor side effects and good tolerability including in older patients, but specific adverse events were not detailed in the available abstract.,Neonatal Semax injection in mice reduced epilepsy susceptibility in one strain (DBA/2J) but not others, indicating strain/population-specific effects that may not generalize.,The free N-terminal amino group of Semax appears critical for copper-related cytoprotective activity; N-terminal acetylation (Ac-Semax) did not protect neuroblastoma cells from Cu(II)-induced toxicity.,Sterile technique is essential for any injectable or intranasal preparation to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification